The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Heart Failure Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.
Some of the key takeaways from the Heart Failure Pipeline Report:
- Companies across the globe are diligently working toward developing novel Heart Failure treatment therapies with a considerable amount of success over the years.
- Heart Failure companies working in the treatment market are Tenaya Therapeutics, Athersys, TransThera Biosciences, SalubrisBio, Ionis Pharmaceuticals, Arena Pharmaceuticals, Palatin Technologies, Bayer HealthCare, Eli Lilly and Company, and others, are developing therapies for the Heart Failure treatment
- Emerging Heart Failure therapies in the different phases of clinical trials are- TN-301, Invimestrocel, TT-00920, JK-07, IONIS AGT LRx, APD418, PL-3994, Finerenone, Tirzepatide, and others are expected to have a significant impact on the Heart Failure market in the coming years.
- In January 2022, MicroPort CRM, an innovative leader in Cardiac Rhythm Management based in France, has recently obtained approval from the PMDA, the Japanese regulatory agency, for its newest series of implantable pacemakers known as the Alizea Bluetooth Pacemaker.
- In January 2022, Medtronic plc was granted approval by Japan’s Ministry of Health, Labor, and Welfare for both sales and reimbursement of the Micra AV Transcatheter Pacing System (TPS).
- In February 2022, Cytokinetics disclosed that the US Food & Drug Administration has acknowledged and officially recorded the company’s New Drug Application (NDA) for omecamtiv mecarbil. This investigational, selective, small molecule cardiac myosin activator is intended for treating heart failure with reduced ejection fraction (HFrEF).
Heart Failure Overview
Heart failure, sometimes called congestive heart failure, is a progressive, chronic illness in which the heart muscle cannot pump enough blood to meet the body’s oxygen and blood requirements. Both the left and right sides of your heart, or both at once, may be affected by heart failure.
Get a Free Sample PDF Report to know more about Heart Failure Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/heart-failure-pipeline-insight
Emerging Heart Failure Drugs Under Different Phases of Clinical Development Include:
- TN-301: Tenaya Therapeutics
- Invimestrocel: Athersys
- TT-00920: TransThera Biosciences
- JK-07: SalubrisBio
- IONIS AGT LRx: Ionis Pharmaceuticals
- APD418: Arena Pharmaceuticals
- PL-3994: Palatin Technologies
- Finerenone: Bayer HealthCare Pharmaceuticals
- Tirzepatide: Eli Lilly and Company
Heart Failure Route of Administration
Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Heart Failure Molecule Type
Heart Failure Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Heart Failure Pipeline Therapeutics Assessment
- Heart Failure Assessment by Product Type
- Heart Failure By Stage and Product Type
- Heart Failure Assessment by Route of Administration
- Heart Failure By Stage and Route of Administration
- Heart Failure Assessment by Molecule Type
- Heart Failure by Stage and Molecule Type
DelveInsight’s Heart Failure Report covers around 90+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Heart Failure product details are provided in the report. Download the Heart Failure pipeline report to learn more about the emerging Heart Failure therapies
Some of the key companies in the Heart Failure Therapeutics Market include:
Key companies developing therapies for Heart Failure are – Abbott Laboratories, Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, Jarvik Heart Inc., Lepu Medical Technology (Beijing)Co.,Ltd., Magenta Medical Ltd, MEDICO S.R.L., Medtronic PLC, Oscor, Inc., OSYPKA MEDICAL, Shree Pacetronix Ltd, and others.
Heart Failure Pipeline Analysis:
The Heart Failure pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
- Heart Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Heart Failure drugs and therapies
Heart Failure Pipeline Market Drivers
- Alongside these drug launches, a new therapeutic strategy is being explored, prevalence of chronic heart failure on the rise, strong collaboration between main stakeholders of therapeutic innovation: scientific community, industry and regulatory agencies are some of the important factors that are fueling the Heart Failure Market.
Heart Failure Pipeline Market Barriers
- However, true surrogate marker for mortality in heart failure (HF) remains elusive, high cost of approved therapies, transition of a clinical HFrEF project from one stage of development to the next is still associated with considerable development risk and other factors are creating obstacles in the Heart Failure Market growth.
Scope of Heart Failure Pipeline Drug Insight
- Coverage: Global
- Key Heart Failure Companies: Tenaya Therapeutics, Athersys, TransThera Biosciences, SalubrisBio, Ionis Pharmaceuticals, Arena Pharmaceuticals, Palatin Technologies, Bayer HealthCare, Eli Lilly and Company, and others
- Key Heart Failure Therapies: TN-301, Invimestrocel, TT-00920, JK-07, IONIS AGT LRx, APD418, PL-3994, Finerenone, Tirzepatide, and others
- Heart Failure Therapeutic Assessment: Heart Failure current marketed and Heart Failure emerging therapies
- Heart Failure Market Dynamics: Heart Failure market drivers and Heart Failure market barriers
Request for Sample PDF Report for Heart Failure Pipeline Assessment and clinical trials
Table of Contents
1. Heart Failure Report Introduction
2. Heart Failure Executive Summary
3. Heart Failure Overview
4. Heart Failure- Analytical Perspective In-depth Commercial Assessment
5. Heart Failure Pipeline Therapeutics
6. Heart Failure Late Stage Products (Phase II/III)
7. Heart Failure Mid Stage Products (Phase II)
8. Heart Failure Early Stage Products (Phase I)
9. Heart Failure Preclinical Stage Products
10. Heart Failure Therapeutics Assessment
11. Heart Failure Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Heart Failure Key Companies
14. Heart Failure Key Products
15. Heart Failure Unmet Needs
16 . Heart Failure Market Drivers and Barriers
17. Heart Failure Future Perspectives and Conclusion
18. Heart Failure Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services